A new design of the continual reassessment method
From MaRDI portal
Publication:5082671
DOI10.1080/03610918.2019.1592191zbMATH Open1497.62291OpenAlexW2934973407MaRDI QIDQ5082671FDOQ5082671
Authors: Weijia Zhang, Xikui Wang, Po Yang 
Publication date: 21 June 2022
Published in: Communications in Statistics. Simulation and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610918.2019.1592191
Recommendations
- Continual reassessment and related dose-finding designs
- A note on continual reassessment method
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Incorporating individual and collective ethics into phase I cancer trial designs
- Characterization of the likelihood continual reassessment method
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- A Random Walk Rule for Phase I Clinical Trials
- Consistency of continual reassessment method under model misspecification
- Miscellanea. A stopping rule for the continual reassessment method
- Group up-and-down designs for dose-finding
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
- Cumulative cohort design for dose-finding
- Continual Reassessment Method: A Likelihood Approach
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
- Continual reassessment designs with early termination
- Adaptive clinical trial designs for phase I cancer studies
- Biometric practicesimple benchmark for complex dose finding studies
Cited In (10)
- A note on continual reassessment method
- Incorporating individual and collective ethics into phase I cancer trial designs
- A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials
- A continual reassessment method without undue risk of toxicity
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Theoretical study of the continual reassessment method
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Characterization of the likelihood continual reassessment method
- Miscellanea. A stopping rule for the continual reassessment method
- A novel doubling-tripling-threshold accepting hybrid algorithm for constructing asymmetric space-filling designs
This page was built for publication: A new design of the continual reassessment method
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5082671)
